Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor
British Journal of Dermatology2018Vol. 179(2), pp. 504–505
Citations Over TimeTop 10% of 2018 papers
Related Papers
- → Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology(2017)27 cited
- → Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib(2013)13 cited
- → Experimental and Clinical Pharmacology:Janus kinase inhibitors in rheumatoid arthritis: Clinical applications(2014)8 cited
- → Tofacitinib: a janus kinase inhibitor for rheumatoid arthritis(2017)1 cited
- Tofacitinib (CP-690,550): A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis(2014)